Treatment of neurolept-induced tardive dyskinesia

被引:39
作者
Jankelowitz, Stacey K. [1 ]
机构
[1] Univ Sydney, Cent Clin Sch, Sydney, NSW 2006, Australia
关键词
tardive dyskinesia; treatment; neuroleptic agents; PLACEBO-CONTROLLED TRIAL; DEEP BRAIN-STIMULATION; SCHIZOPHRENIA SPECTRUM DISORDERS; HYPERKINETIC MOVEMENT-DISORDERS; GENETIC ASSOCIATION ANALYSIS; VITAMIN-E TREATMENT; OPEN-LABEL TRIAL; 1A2; CYP1A2; GENE; DOUBLE-BLIND; RECEPTOR GENE;
D O I
10.2147/NDT.S30767
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Tardive dyskinesia (TDK) includes orobuccolingual movements and "piano-playing" movements of the limbs. It is a movement disorder of delayed onset that can occur in the setting of neuroleptic treatment as well as in other diseases and following treatment with other drugs. The specific pathophysiology resulting in TDK is still not completely understood but possible mechanisms include postsynaptic dopamine receptor hypersensitivity, abnormalities of striatal gamma-aminobutyric acid (GABA) neurons, and degeneration of striatal cholinergic interneurons. More recently, the theory of synaptic plasticity has been proposed. Considering these proposed mechanisms of disease, therapeutic interventions have attempted to manipulate dopamine, GABA, acetylcholine, norepinephrine and serotonin pathways and receptors. The data for the effectiveness of each class of drugs and the side effects were considered in turn.
引用
收藏
页码:1371 / 1380
页数:10
相关论文
共 50 条
[41]   Amisulpride-induced tardive dyskinesia [J].
Fountoulakis, Konstantinos N. ;
Panagiotidis, Panagiotis ;
Siamouli, Melina ;
Kantartzis, Sotiris ;
Mavridis, Theocharis ;
Iacovides, Apostolos ;
Kaprinis, George .
SCHIZOPHRENIA RESEARCH, 2006, 88 (1-3) :232-234
[42]   Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs [J].
Seigneurie, A. -S. ;
Sauvanaud, F. ;
Limosin, F. .
ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2016, 42 (03) :248-254
[43]   Tardive dyskinesia: Who gets it and why [J].
Frei, Karen .
PARKINSONISM & RELATED DISORDERS, 2019, 59 :151-154
[44]   A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine [J].
Patel, Rikinkumar S. ;
Mansuri, Zeeshan ;
Motiwala, Fatima ;
Saeed, Hina ;
Jannareddy, Namrata ;
Patel, Hiren ;
Zafar, Muhammad Khalid .
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2019, 9
[45]   VMAT2 inhibitors for the treatment of tardive dyskinesia [J].
Scorr, Laura M. ;
Factor, Stewart A. .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 389 :43-47
[46]   Effectiveness of melatonin in tardive dyskinesia. [J].
Castro, Fernando ;
Carrizo, Edgardo ;
Prieto de Rincon, Dexy ;
Alberto Rincon, Ciro ;
Asian, Triana ;
Medina-Leendertz, Shirley ;
Bonilla, Ernesto .
INVESTIGACION CLINICA, 2011, 52 (03) :252-260
[47]   TARDIVE-DYSKINESIA IN NEUROLEPTIC TREATMENT [J].
WETTERLING, T .
NERVENHEILKUNDE, 1994, 13 (05) :212-217
[48]   Botulinum toxin as a treatment for tardive dyskinesia [J].
van Harten, Peter N. ;
Hovestadt, Ad .
MOVEMENT DISORDERS, 2006, 21 (08) :1276-1277
[49]   Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management [J].
Salem, Haitham ;
Pigott, Teresa ;
Zhang, Xiang Y. ;
Zeni, Cristian P. ;
Teixeira, Antonio L. .
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (09) :883-894
[50]   Vitamin E in the treatment of tardive dyskinesia [J].
Boomershine, KH ;
Shelton, PS ;
Boomershine, JE .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (11) :1195-1202